Wall Street Has a Mixed Opinion on ​Astrana Health (ASTH), Here’s Why

​Astrana Health, Inc. (NASDAQ:ASTH) is one of the Fast-Growing Small Cap Stocks to Buy According to Analysts. Wall Street has a mixed opinion on Astrana Health, Inc. (NASDAQ:ASTH). On November 12, Jaliendra Singh from Truist Financial reiterated a Buy rating on the stock with a price target of $37. However, earlier on November 10, Ryan Langston from TD Cowen lowered the price target on the stock from $40 to $35, while keeping a Buy rating.

​The mixed outlook follows the company’s fiscal Q3 2025 results, announced on November 6. The revenue grew 99.71% year-over-year to $956.05 million, surpassing estimates by $3.22 million. However, the EPS of $0.01 fell short of the consensus by $0.43. Management attributed the growth to being driven by the integration of Prospect Health into the company, followed by solid organizational growth across its core business.

​However, looking ahead, management is expecting headwinds in its Medicaid and exchange business. Therefore, Astrana Health, Inc. (NASDAQ:ASTH) lowered its full-year revenue guidance to a range of $3.1 billion and $3.18 billion, down from the previous range of $3.1 billion to $3.3 billion. The Adjusted EBITDA guidance was also lowered to a range of $200 million and $210 million from the previous range of $215 million and $225 million.

​The analyst Ryan Langston of TD Cowen noted that this reduced outlook reflects caution on Medicaid and the VBC environment.

​Astrana Health, Inc. (NASDAQ:ASTH) is a physician-centered, technology-powered healthcare company that focuses on delivering coordinated, high-quality care to patients through its network of providers.

READ NEXT: 30 Stocks That Should Double in 3 Years and 11 Hidden AI Stocks to Buy Right Now.

Disclosure: None. This article is originally published at Insider Monkey.